## Jonathan M. Lee

## Partner, New York

Mergers and Acquisitions

T: 212.735.3454 jonathan.lee@skadden.com

## Education

J.D., Georgetown University Law Center, 2016 (*magna cum laude*; Order of the Coif; Managing Editor, *The Georgetown Law Journal*)

M.S., Georgetown University, 2012

B.A., Cornell University, 2011

## **Bar Admissions**

New York

Jonathan M. Lee focuses on mergers and acquisitions, corporate governance, securities and general corporate law matters. Mr. Lee regularly advises public and private companies in a variety of U.S. and cross-border transactions, including acquisitions, dispositions, auctions, carve-outs, business separations, investments, financings, restructurings, financial advisor engagements and SPAC transactions. In recognition of his work, Mr. Lee has been named to Lawdragon's 500 X — The Next Generation list and repeatedly honored as one of *Best Lawyers*' Ones To Watch in America.

Selected representations by Mr. Lee include:

- DuPont de Nemours, Inc. in its announced intent to separate via a tax-free spin-off into two stand-alone public companies focused on its electronics and diversified industrials businesses
- International Flavors & Fragrances Inc. in the \$810 million sale of its cosmetic ingredients business to Clariant AG
- Molina Healthcare, Inc. in its \$350 million acquisition of ConnectiCare, a leading health plan in the state of Connecticut
- the CEO of Radius Global Infrastructure, Inc. in the company's \$3 billion acquisition by EQT Active Core Infrastructure and Public Sector Pension Investment Board
- SMS Assist, L.L.C. in its \$950 million merger with Lessen Inc.
- Theravance Biopharma in the \$1.5 billion sale of its interests in Theravance Royalty Company LLC, representing its TRELEGY ELLIPTA royalty interests, to Royalty Pharma plc and related \$40 million investment in Theravance Biopharma's ampreloxetine program
- Red Hat, Inc. in its \$34 billion acquisition by IBM
- Express Scripts Holding Company in its \$67 billion acquisition by Cigna Corporation
- Danaher Corporation in its acquisition of InSilixa, Inc.
- Orum Therapeutics, Inc. in the \$180 million sale of its ORM-6151 program to Bristol-Myers Squibb Company
- FaZe Clan Inc. in its \$1 billion merger with B. Riley Principal 150 Merger Corp.
- Aspirational Consumer Lifestyle Corp. in its \$2.1 billion merger with Wheels Up Partners Holdings LLC
- Social Capital Hedosophia in its \$3.7 billion merger with Clover Health Investments, Corp.
- AP WIP Investments Holdings in its \$860 million acquisition by Landscape Acquisition Holdings
- CPI International, Inc. (previously a portfolio company of Veritas Capital and now a portfolio company of Odyssey Investment Partners) in its:
  - acquisition of SATCOM Technologies, the antenna systems business of General Dynamics Mission Systems
  - disposition of ASC Signal Holdings Corporation to Kratos Defense & Security Solutions, Inc.
- Veritas Capital and certain of its portfolio companies in various transactions and corporate matters, including Verscend Technologies, Inc. (n/k/a Cotiviti, Inc., a portfolio company of Veritas Capital) in its \$4.9 billion acquisition of Cotiviti Holdings, Inc.

- Rite Aid Corporation in various transactions and corporate matters, including its:
  - \$4.4 billion sale of 1,932 stores and related assets to Walgreens Boots Alliance, Inc.
  - proposed (but terminated) merger with Albertsons Companies, Inc.
- Mars, Incorporated in various transactions and corporate matters
- Goldman Sachs & Co. LLC as financial advisor in various transactions, including to:
  - Cameco Corporation in connection with its and Brookfield Renewable Partners' strategic partnership's \$7.9 billion acquisition of Westinghouse Electric Company
  - Signify Health, Inc. in its \$8 billion acquisition by CVS Pharmacy, Inc.
- Centerview Partners LLC as financial advisor in various transactions, including to:
  - Cerevel Therapeutics Holdings, Inc. in its \$8.7 billion acquisition by AbbVie Inc.
  - Inhibrx, Inc. in its \$2.2 billion sale of INBRX-101 to Sanofi
  - G1 Therapeutics, Inc. in its \$405 million acquisition by Pharmacosmos A/S

Mr. Lee is actively involved in Skadden's training and recruiting programs.